TNX-1700 / Tonix - LARVOL DELTA

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models (GlobeNewswire) - "Tonix Pharmaceuticals...announced the publication of a paper...in the peer-reviewed journal Cancer Cell, that represents a collaboration between scientists at Tonix and Columbia University’s Medical School and presents data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival and decreased metastases in animal models of gastric cancer....Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone. mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion."

Preclinical • Gastric Cancer

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire) - "The presentation...demonstrated positive data in gastric cancer animal models. In the AACR presentation, a fusion protein of murine trefoil factor family member 2- murine serum albumin (mTFF2-MSA) was studied. Tonix is developing human TFF2-human serum albumin (hTFF2-HAS) as TNX-1700....Data presented in the poster demonstrated that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. Treatment with TFF2-MSA, in combination with an anti-PD1 antibody, induced robust anti-tumoral CD8+ T cell responses, inhibiting tumor invasion. TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, highlighting the potential negative correlation between TFF2 and PMN-MDSCs levels."

Preclinical • Gastric Cancer

Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023 (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...today announced a poster presentation showing research results for mTNX-1700 (murine trefoil factor family member 2- murine serum albumin, or mTFF2-MSA) at the Seventh International Cancer Immunotherapy Conference 2023 (CICON23): Translating Science into Survival, being held September 20-23, 2023, in Milan, Italy....The poster presentation...includes data demonstrating that the novel fusion protein, mTNX-1700 has single agent activity and can improve on the therapeutic effects of anti-PD-1 in treating syngeneic mouse models of advanced colorectal cancer. In two models, mTNX-1700 increases survival rates and suppresses tumor growth. Additive tumor growth suppression effects were observed when mTNX-1700 and anti-PD-1 were used in combination."

Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023 (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp....today announced a poster presentation at the Seventh International Cancer Immunotherapy Conference 2023 (CICON23): Translating Science into Survival. The Conference is being held September 20-23, 2023, in Milan, Italy."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...announced the presentation of two posters with research results on TNX-1700 (recombinant TFF2 – albumin fusion peptide) at the American Association for Cancer Research (AACR) Annual Meeting, held April 14-19, 2023, in Orlando, Fla...The data show that mTNX-1700 and anti-PD-1 monotherapy each were able to evoke anti-tumor immunity in the MC38 and CT26.wt models of colorectal cancer, and that mTNX-1700 augmented the anti-tumor efficacy of anti-PD-1 therapy in both of these colorectal cancer models. The poster presentation...includes data showing that targeting MDSCs using mTNX-1700 synergizes with PD-1 blockade therapy in advanced and metastatic syngeneic mouse models of diffuse-type gastric cancer, suggesting combination therapy of mTNX-1700 and PD-1 blockade may also be applicable to gastric cancer."

Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...announced that two posters with research results on TNX-1700 (recombinant TFF2 – albumin fusion peptide) will be presented as posters at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Fla. These data demonstrate that targeting myeloid-derived suppressor cells (MDSCs) using mTNX-1700, a murine TFF2 – murine serum albumin fusion peptide (mTFF2-MSA) provides additive benefits to PD-1 blockade therapy in advanced and metastatic syngeneic mouse models of colorectal and gastric cancer."

Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance” (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...announced that preclinical results of mTNX-1700 (recombinant murine TFF2-murine serum albumin, or MSA, fusion protein) were presented in a poster at the Keystone Symposia, 'Cancer Immunotherapy: Mechanisms of Response Versus Resistance' on March 6, 2023, at the Fairmont Banff Springs Conference Center in Banff, Alberta, Canada....The data show that mTNX-1700 and anti-PD-1 monotherapy each were able to evoke anti-tumor immunity in the MC38 model of colorectal cancer, and that mTNX-1700 augmented the anti-tumor efficacy of anti-PD-1 therapy in two different colorectal cancer models. Tonix is developing TNX-1700 (recombinant human TFF2-human serum albumin or HSA) for the treatment of colon and gastric cancers."

Preclinical • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...announced that it has entered into a research collaboration with Columbia University (Columbia) focused on advancing recombinant trefoil factor family 2 (rTFF2)-based therapeutic candidates (TNX-1700) in the treatment of gastric and colorectal cancers. Tonix licensed worldwide rights to develop and commercialize products related to Columbia’s rTFF2 technology in 20191, and key patent claims have recently issued in the U.S...The studies will be conducted by scientists at Columbia University under the direction of Timothy Wang, M.D., professor of medicine and Chief of the Division of Digestive and Liver Diseases at Columbia University Vagelos College of Physicians and Surgeons."

Licensing / partnership • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers (GlobeNewswire) - "Tonix Pharmaceuticals Holding Corp...announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,167,010 on November 9, 2021. The patent, entitled 'Trefoil Family Factor Proteins and Uses Thereof,' includes claims directed to an isolated polypeptide comprising a carboxy-terminal (CTP) domain of the beta subunit of the human chorionic gonadotropin (hCG) fused to a TFF2 protein (TFF2-CTP). This patent, excluding possible patent term extensions, is expected to provide U.S. market exclusivity until April 2, 2033."

Patent • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020 - "The data show that anti-PD-1 monotherapy was unable to evoke anti-tumor immunity in this model of colorectal cancer, but TFF2-CTP augmented the efficacy of anti-PD-1 therapy. Anti-PD-1 in combination with TFF2-CTP showed greater anti-tumor activity in PD-L1-overexpressing mice. Tonix is developing TNX-1700 (rTFF2-CTP) for the treatment of gastric, colon and pancreatic cancers under a license from Columbia University."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology